PROCEPT BioRobotics stands out in the robotics screener because it has successfully commercialized an innovative robotic platform that addresses a massive, underserved market in urology while maintaining a capital-efficient business model. The company’s AquaBeam system represents a genuine technological differentiation in surgical robotics—rather than pursuing the costly race to build general-purpose surgical platforms like Intuitive, PROCEPT focused its engineering efforts on automating a specific procedure (aquablation for benign prostatic hyperplasia) where precision and reproducibility create clear clinical and economic advantages. This focused approach has allowed PROCEPT to achieve FDA clearance, build a growing installed base, and maintain healthier unit economics than many competitors attempting to develop platforms for dozens of different surgical applications.
What separates PROCEPT from other robotics companies is not just the technology but the market thesis behind it. The global market for BPH treatment is estimated in the billions annually, with hundreds of thousands of procedures performed each year, yet for decades the standard of care relied on open surgery, TURP (transurethral resection of the prostate), or less-effective minimally invasive techniques. PROCEPT identified an unmet need where a targeted robotic solution could deliver better outcomes to surgeons and hospitals while being economically viable—this is the opposite of many robotics ventures that chase applications where the clinical need is already well-served by existing technology or where the market is too small to justify development costs.
Table of Contents
- Why Surgical Robotics Investors Overlook Focused Platforms
- The AquaBeam System’s Technological Differentiation and Manufacturing Reality
- Market Position and Clinical Adoption Dynamics
- Capital Efficiency and Unit Economics Compared to Platform-Based Competitors
- Competitive and Regulatory Risks in the Medical Robotics Space
- Intellectual Property and Technical Barriers to Entry
- Expansion Strategy and Unproven Adjacent Markets
Why Surgical Robotics Investors Overlook Focused Platforms
The robotics investment community has historically gravitated toward general-purpose surgical systems because they appear to offer larger total addressable markets. Intuitive Surgical dominates this space with the da Vinci system, which can be configured for dozens of different surgical specialties, making it appealing to large hospital systems and justifying premium pricing. However, this generalist approach requires enormous R&D budgets, extensive clinical validation across multiple specialties, regulatory approvals in many countries, and global sales infrastructure. Smaller companies attempting to compete on the same basis typically burn through capital without achieving meaningful market share. PROCEPT rejected this playbook and instead built a platform specifically optimized for prostate surgery, where the anatomical constraints and procedural requirements are well-understood, repeatable, and mechanically well-suited to automation.
This is a counterintuitive strategic choice in an industry dominated by dreams of multi-specialty platforms, but it allows PROCEPT to compete on capital efficiency rather than scale. A surgeon performing aquablation with AquaBeam receives real-time imaging, water jet guidance, and procedural consistency that reduces variability between operations and between providers—benefits that are measurable and clinically meaningful rather than theoretical. The limitation of this strategy, however, is that it constrains PROCEPT’s addressable market compared to Intuitive’s platform approach. While the BPH market is large and growing (driven by aging populations), it is fundamentally smaller than the sum of all surgical procedures where a general-purpose robot could theoretically be deployed. This means PROCEPT will never become a Intuitive-scale company unless it successfully expands to adjacent urology procedures or entirely new surgical domains—a transition that would require new R&D investment and clinical validation, diluting the original advantage of specialization.
The AquaBeam System’s Technological Differentiation and Manufacturing Reality
The AquaBeam system uses focused waterjet technology to ablate prostate tissue with precision, combined with real-time ultrasound imaging and robotic arm positioning to ensure consistent, reproducible results. This is not a novel concept—water jet cutting and surgical ablation are established techniques—but integrating them into a fully robotic platform with the necessary safety redundancies, imaging clarity, and procedural ergonomics required years of engineering and clinical development. The value proposition to surgeons is significant: more predictable outcomes, lower rates of urinary retention (a common complication of traditional BPH surgery), and shorter operative times compared to manual TURP. From a manufacturing perspective, AquaBeam is more complex than many surgical instruments but simpler than general-purpose surgical robots. It requires precision engineering for the waterjet delivery system, the imaging components, and the robotic arm, but does not need the extreme dexterity, force feedback systems, or multi-DOF instrument compatibility that a platform like da Vinci demands.
This reduces procept‘s engineering and manufacturing burden compared to what Intuitive or other generalist roboticists must support. The trade-off is that each new procedure PROCEPT wants to address would require meaningful additional development, whereas Intuitive’s platform can be extended with new instruments and applications with less fundamental redesign. One practical concern is that aquablation, while effective, still competes with other minimally invasive BPH treatments—including UroLift, temporary urethral stents, and pharmaceutical management. Some urologists and patients may prefer these less invasive alternatives for milder cases, or may gravitate toward traditional TURP despite its higher complication rates because they already have infrastructure and training for it. PROCEPT’s growth depends on persuading a sufficient fraction of the BPH-treatment market to adopt its technology, which means both clinical education and reimbursement support.
Market Position and Clinical Adoption Dynamics
PROCEPT has achieved FDA clearance for AquaBeam in the United States and has begun building an installed base of units in hospitals and surgery centers. The adoption curve for a new surgical technology is typically slower than for software or hardware in other industries because surgeon training, credentialing, reimbursement authorization, and hospital procurement cycles all create friction. Unlike Intuitive, which benefits from decades of surgeon familiarity and standardized reimbursement, PROCEPT must educate each hospital about its offering, negotiate reimbursement rates with payers, and manage surgeon adoption and retention. However, PROCEPT has a timing advantage.
The global population is aging, BPH prevalence is rising, and many urologists are frustrated with the trade-offs in existing treatment modalities. Additionally, PROCEPT entered a market where the incumbent technology (TURP and open prostatectomy) is mature and well-established, meaning there is less resistance from entrenched rival device companies and more openness to innovation. Hospitals are increasingly willing to trial new technologies in high-volume procedures where small improvements in outcomes or efficiency can translate to significant cost savings or patient satisfaction gains. A concrete example of this dynamic: hospitals performing high volumes of BPH procedures (potentially 50-100+ cases annually at a large medical center) can justify the capital investment in an AquaBeam system if the technology reduces operative time by 30-50 minutes per case, lowers reoperation rates for complications, or improves patient satisfaction scores. These are measurable, replicable benefits that create a business case beyond mere novelty or surgeon preference.
Capital Efficiency and Unit Economics Compared to Platform-Based Competitors
One of PROCEPT’s strongest appeals to investors and hospital buyers is its capital efficiency relative to general-purpose surgical robots. A da Vinci system can cost $1 million to $2 million per unit, plus annual service contracts, training, and extended warranties that add hundreds of thousands of dollars over a system’s lifetime. The hospitals purchasing these systems must justify the investment across multiple surgical specialties to achieve payback. In contrast, PROCEPT’s AquaBeam system, while still representing a significant capital commitment, targets a narrower use case with higher-volume potential within that niche. Furthermore, PROCEPT’s go-to-market strategy emphasizes surgeon credentialing and training, which can be more efficient than Intuitive’s global service and support infrastructure.
This doesn’t mean PROCEPT needs less support—robotic systems require technical expertise and maintenance—but the focused scope of application allows PROCEPT to build support infrastructure tailored to a specific procedure rather than attempting to support dozens of surgical specialties across multiple organ systems. The trade-off is that PROCEPT’s total addressable market is smaller, which constrains revenue growth and limits the eventual scale of the company’s business. Intuitive can sell da Vinci systems globally across hundreds of surgical specialties, creating multiple revenue streams and resilience if adoption stalls in any single procedure. PROCEPT’s growth is inherently tied to adoption of aquablation for BPH treatment, which, while a large market, does not offer the same diversification. If aquablation adoption plateaus or if competitors develop alternative minimally invasive BPH treatments that prove superior, PROCEPT would face slower growth unless it successfully expands into adjacent applications.
Competitive and Regulatory Risks in the Medical Robotics Space
Medical robotics as an industry faces increasing scrutiny from regulators, payers, and hospital administrators around outcomes data, cost-effectiveness, and necessity. The FDA has begun requesting more rigorous clinical evidence from surgical robotics manufacturers, and Medicare and private payers are becoming more selective about which robotic procedures they will reimburse at premium rates. This creates a risk for any robotics company whose technology has not yet achieved widespread payer acceptance or whose clinical evidence base is still being built. For PROCEPT specifically, the risk is that payers or hospital systems may demand lower reimbursement rates for aquablation, arguing that the clinical benefits do not justify a significant price premium over traditional TURP or other minimally invasive BPH treatments.
Additionally, if other companies develop competing aquablation platforms or if entirely new BPH treatment modalities are invented, PROCEPT could face margin compression or market-share erosion. The company’s narrow focus on BPH aquablation means it lacks the diversification of larger robotic platforms, making it more vulnerable to shifts in reimbursement policy or clinical preferences within its primary application. Another practical concern is surgeon adoption velocity. While some surgeons and hospitals embrace new technology eagerly, others adopt slowly or resist altogether. If adoption of aquablation is slower than PROCEPT’s projections, the company could face margin pressure on fixed manufacturing and R&D costs spread over a smaller revenue base.
Intellectual Property and Technical Barriers to Entry
PROCEPT has built a portfolio of patents around its waterjet ablation technology, robotic positioning systems, and integrated imaging and procedural software. These patents create a technical moat that protects PROCEPT from immediate competition and give the company pricing power and negotiating leverage with hospitals and surgeons. Unlike software patents, which can be quickly worked around, hardware and manufacturing patents for surgical systems have stronger protective value because reverse engineering a complex robotic platform requires substantial capital and regulatory clearance.
However, patents have a finite life, and competitors with sufficient capital and expertise could eventually develop non-infringing alternative designs. Intuitive Surgical, for instance, has successfully defended its market position not only through patents but through surgeon training infrastructure, reimbursement relationships, and network effects where hospitals want compatibility with established workflows. PROCEPT must continue innovating and expanding its clinical evidence base to maintain differentiation beyond patent protection alone.
Expansion Strategy and Unproven Adjacent Markets
Looking at PROCEPT’s long-term positioning, the critical question is whether the company can successfully expand aquablation technology into adjacent urological procedures—such as treatment of urethral strictures, bladder tumors, or kidney stones—or entirely new surgical domains. If the core AquaBeam platform can be adapted to address multiple high-volume surgical problems, the company’s total addressable market expands significantly and its investment in manufacturing and sales infrastructure becomes more efficient. However, each new indication requires separate clinical validation, FDA clearance, surgeon training, and payer negotiation.
PROCEPT has not yet proven it can successfully execute this expansion, so it remains a long-term thesis rather than a current strength. For now, PROCEPT’s standing in the robotics screener rests on its execution in prostate aquablation, its capital-efficient business model, and its positioning in a large, growing market where the incumbent technology is mature and ripe for disruption. Whether this advantage persists depends on PROCEPT’s ability to drive adoption faster than competitors can respond and to expand its platform’s addressable market without sacrificing the focused engineering excellence that created its initial edge.
- —
